Fifth Amendment To Wholesale Product Purchase Agreement
Exhibit 10.59
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Fifth Amendment
To
Wholesale Product Purchase Agreement
This Fifth Amendment to Wholesale Product Purchase Agreement (this “Fifth Amendment” is made as of November 13, 2019, (the “Amendment Effective Date”), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation having offices at 000 Xxxxxxxxxx Xxxx, Xxxx Xxxx, Xxxxxxx 00000, (“Distributor”), and United Therapeutics Corporation (“UT”), a Delaware corporation having offices at 0000 Xxxxxx Xxxxxx, Xxxxxx Xxxxxx, Xxxxxxxx. Distributor and UT are each referred to in this Agreement as a “Party,” collectively, the “Parties.”
WHEREAS, the Parties entered into that certain Wholesale Product Purchase Agreement dated as of January 1, 2018, as amended, (the “Agreement”); and
WHEREAS, the Parties desire to amend the Agreement as provided herein, with effect from the Amendment Effective Date.
NOW THEREFORE, In consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:
1. Exhibit B, Section II shall be deleted in its entirety and replaced with the following:
[***]
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
2. The following row is deleted from the table in Exhibit B, Section III (Service Fees):
|
[***] |
[***] |
[***] |
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
3. The following row is added to the table in Exhibit B, Section III (Service Fees) and is intended to cover all services related to the [***]:
|
[***] |
[***] |
[***] |
4. Exhibit F shall be deleted in its entirety and replaced with the Exhibit F attached hereto.
5. Except as amended and supplemented hereby, all of the terms and conditions of the Agreement shall remain and continue in full force and effect and apply hereto.
[signature page follows]
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
In witness whereof, each of the undersigned, duly authorized, has executed this Fifth Amendment, effective as of the Amendment Effective Date.
|
Priority Healthcare Distribution, Inc. |
|
United Therapeutics Corporation |
||
|
|
|
|
||
|
|
|
|
||
|
By: |
/s/ Xxxx English |
|
By: |
/s/ Xxxxx X. Xxxx |
|
|
|
|
|
|
|
Print Name: |
Xxxx English |
|
Print Name: |
Xxxxx X. Xxxx |
|
|
|
|
|
|
|
Title: |
President, Curascript SD |
|
Title: |
SVP, Strategic Operations |
|
|
|
|
|
|
|
Date: |
11/15/2019 – 1:41 PM CST |
|
Date: |
Nov 18, 2019 |
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Exhibit F
[***]
